Literature DB >> 15095405

IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.

E Gregory MacEwen1, Josep Pastor, Jonathan Kutzke, Rachel Tsan, Ilene D Kurzman, Douglas H Thamm, Mike Wilson, Robert Radinsky.   

Abstract

To further define the role of insulin-like growth factor-1 (IGF-1) and its receptor (IGF-1R) in osteosarcoma (OS), human OS cell lines with low (SAOS-2) and high (SAOS-LM2) metastatic potential and three canine OS-derived cell lines were studied. Cell lines were evaluated for: IGF-1R expression; expression of IGF binding proteins (IGFBPs); effect of IGF-1 on tumor cell growth, invasion, expression of urokinase plasminogen activator (uPA), and soluble uPA receptor (suPAR), and; ectopic and orthotopic tumorigenicity of the canine OS cells in athymic mice. All cell lines exhibited steady-state mRNA expression of IGF-1R. The SAOS-2 and SAOS-LM2 cells expressed 9,138 and 10,234 cell-associated binding sites, respectively. Canine OS cells expressed from 1,728 to 3,883 binding sites. Two IGF-1-treated cell lines displayed enhanced proliferation. Two cell lines formed colonies in semisolid media, and IGF-1 increased colony number. Matrigel invasion was enhanced in one cell line following IGF-1 treatment. uPA and suPAR were unchanged in SAOS-2 and SAOS-LM2 cells following IGF-1 treatment, but the highly metastatic OS line SAOS-LM2 expressed five times more suPAR and displayed enhanced invasion compared to the parental, low metastatic SAOS-2. IGFBP-5 was detected in four of five cell lines, and IGFBP-3 was detected in two canine OS cell lines. Two canine OS lines were tumorigenic, and one metastasized spontaneously. In conclusion, OS cells express IGF-1R, which can contribute to their growth and invasion. There is suggestive evidence that increasing receptor number may contribute to in vivo tumorigenesis. Additional studies are needed to determine how IGF-1/IGF-1R interactions contribute to the malignant phenotype of OS. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095405     DOI: 10.1002/jcb.20046

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  40 in total

1.  Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Authors:  Brenda Weigel; Suman Malempati; Joel M Reid; Stephan D Voss; Steven Y Cho; Helen X Chen; Mark Krailo; Doojduen Villaluna; Peter C Adamson; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2013-08-17       Impact factor: 3.167

Review 2.  Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency.

Authors:  Jaime Guevara-Aguirre; Arlan L Rosenbloom
Journal:  Diabetologia       Date:  2014-10-15       Impact factor: 10.122

3.  A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.

Authors:  Eduardo Laborda; Cristina Puig-Saus; Alba Rodriguez-García; Rafael Moreno; Manel Cascalló; Josep Pastor; Ramon Alemany
Journal:  Mol Ther       Date:  2014-01-22       Impact factor: 11.454

4.  Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Suman Malempati; Brenda Weigel; Ashish M Ingle; Charlotte H Ahern; Julie M Carroll; Charles T Roberts; Joel M Reid; Stephen Schmechel; Stephan D Voss; Steven Y Cho; Helen X Chen; Mark D Krailo; Peter C Adamson; Susan M Blaney
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 5.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

6.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

Review 7.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

8.  A clinically relevant mouse model of canine osteosarcoma with spontaneous metastasis.

Authors:  Beth K Chaffee; Matthew J Allen
Journal:  In Vivo       Date:  2013 Sep-Oct       Impact factor: 2.155

Review 9.  Pediatric oncology.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Curr Opin Chem Biol       Date:  2007-07-24       Impact factor: 8.822

Review 10.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.